KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q4 2025 value amounting to $38.3 million.

  • Vertex Pharmaceuticals' Change in Account Payables rose 35595.24% to $38.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $36.8 million, marking a year-over-year decrease of 2565.66%. This contributed to the annual value of $36.8 million for FY2025, which is 2565.66% down from last year.
  • As of Q4 2025, Vertex Pharmaceuticals' Change in Account Payables stood at $38.3 million, which was up 35595.24% from -$35.3 million recorded in Q3 2025.
  • Vertex Pharmaceuticals' 5-year Change in Account Payables high stood at $159.9 million for Q4 2022, and its period low was -$69.9 million during Q3 2022.
  • Its 5-year average for Change in Account Payables is $14.4 million, with a median of $8.0 million in 2024.
  • As far as peak fluctuations go, Vertex Pharmaceuticals' Change in Account Payables crashed by 342524.27% in 2021, and later surged by 2610000.0% in 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' Change in Account Payables (Quarter) stood at $53.9 million in 2021, then surged by 196.66% to $159.9 million in 2022, then crashed by 119.89% to -$31.8 million in 2023, then surged by 126.42% to $8.4 million in 2024, then surged by 355.95% to $38.3 million in 2025.
  • Its last three reported values are $38.3 million in Q4 2025, -$35.3 million for Q3 2025, and $7.6 million during Q2 2025.